Holen Sie sich die Stockscreener-App
7.90
0.38%
-0.08
Schlusskurs vom Vortag:
$7.98
Offen:
$8.08
24-Stunden-Volumen:
18,383
Relative Volume:
0.03
Marktkapitalisierung:
$921.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-174.61M
KGV:
-3.7441
EPS:
-2.11
Netto-Cashflow:
$-165.54M
1W Leistung:
-9.14%
1M Leistung:
-2.21%
6M Leistung:
-11.17%
1J Leistung:
+4.74%
1-Tages-Spanne:
$7.85
$8.0992
1-Wochen-Bereich:
$7.675
$8.85
52-Wochen-Spanne:
$7.00
$16.63
89 Bio Inc Stock (ETNB) Company Profile
Firmenname
89 Bio Inc
Sektor
Branche
Telefon
(415) 432-9270
Adresse
142 SANSOME STREET, SAN FRANCISCO, CA
Vergleichen Sie ETNB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ETNB | 7.90 | 921.95M | 0 | -174.61M | -165.54M | -2.11 |
| VRTX | 447.53 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.03 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.31 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-05-12 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-26 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-19 | Eingeleitet | Raymond James | Strong Buy |
| 2020-09-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-23 | Eingeleitet | BTIG Research | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-12-09 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-12-09 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-12-09 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
89 Bio Inc Aktie (ETNB) Neueste Nachrichten
89Bio Inc. Reports Q3 2024 Financial Results - TipRanks
RA CAPITAL MANAGEMENT, L.P. Increases Stake in 89bio Inc - GuruFocus.com
89bio Inc.’s $125 Million Common Stock Offering - Global Legal Chronicle
Syncona building Slingshot incubator; Trace launches with $101M - BioCentury
89bio reports potential MASH treatment progress By Investing.com - Investing.com Canada
89bio reports potential MASH treatment progress - Investing.com
89bio's Pegozafermin Shows Promising Results in Advanced MASH Treatment Trial | ETNB Stock News - StockTitan
89bio, Inc. announces public offering and warrant issuance - Investing.com
Janus Henderson Group PLC's Strategic Acquisition in 89bio Inc - GuruFocus.com
FY2024 EPS Estimates for 89bio Lowered by Cantor Fitzgerald - MarketBeat
HC Wainwright Issues Pessimistic Estimate for 89bio Earnings - MarketBeat
89bio announces $100 million public stock offering - Investing.com India
SEC Form 424B5 filed by 89bio Inc. - Quantisnow
89bio drops 2%, prices $125M stock offering - MSN
89bio announces $100 million public stock offering By Investing.com - Investing.com Australia
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
89bio Raises $125M in Upsized Public Offering at $8.50 Per Share | ETNB Stock News - StockTitan
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
ETNB89bio, Inc. Latest Stock News & Market Updates - StockTitan
89bio announces proposed underwritten public offering of common stock and pre-funded warrants - MSN
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
BioLife Solutions Surges 30% in Q3 Revenue, Slashes Net Loss by 89% | Earnings Report | BLFS Stock News - StockTitan
89bio Launches $100M Public Offering to Advance Pegozafermin Development | ETNB | ETNB Stock News - StockTitan
GLP-1s push into MASH as semaglutide 2.4 mg hits endpoints - BioWorld Online
89bio Inc (ETNB) Quarterly 10-Q Report - Quartzy
89bio, Inc. (NASDAQ:ETNB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
HC Wainwright Reaffirms Buy Rating for 89bio (NASDAQ:ETNB) - MarketBeat
FY2028 Earnings Estimate for 89bio Issued By Leerink Partnrs - MarketBeat
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Raymond James Issues Pessimistic Forecast for 89bio (NASDAQ:ETNB) Stock Price - MarketBeat
89bio Reports Third Quarter 2024 Financial Results and Corporate UpdatesSAN FRANCISCO, November 7, 2024 (GLOBE NEWSWIRE) – On November 7, 2024, 89bio, Inc. (NASDAQ: ETNB), a clinical-stage biopharmaceutical company focusing on innovativ - Defense World
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
89bio Inc (ETNB) Has A Gold Mine On Its Hands - Stocks Register
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Harbor Capital Advisors Inc. Purchases 142,032 Shares of 89bio, Inc. (NASDAQ:ETNB) - MarketBeat
89bio to Participate in the UBS Global Healthcare Conference - The Manila Times
89bio to Present at UBS Global Healthcare Conference: Key Investor Updates Coming | ETNB Stock News - StockTitan
Lyft Inc Cl A (LYFT-Q) QuotePress Release - The Globe and Mail
UBS Group Ag ADR (UBS-N) QuotePress Release - The Globe and Mail
89bio (NASDAQ:ETNB) Shares Gap DownHere's What Happened - MarketBeat
Block Inc (SQ-N) QuotePress Release - The Globe and Mail
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance
89bio's chief technical operations officer sells $226,994 in stock - Investing.com India
89bio's chief technical operations officer sells $226,994 in stock By Investing.com - Investing.com Australia
89bio (NASDAQ:ETNB) Trading 7.3% HigherStill a Buy? - MarketBeat
Coinbase Global Inc Cl A (COIN-Q) QuotePress Release - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
89Bio: Surviving A Competitive SpaceFor Now (NASDAQ:ETNB) - Seeking Alpha
Global Severe Hypertriglyceridemia (SHTG) Treatment Market Set to Reach USD 2675.37 Million by 2033 - PharmiWeb.com
Bank of America Corp (BAC-N) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Finanzdaten der 89 Bio Inc-Aktie (ETNB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):